JP7824969B2 - 抗ｓ１００ａ４ヒト化抗体、使用及び方法 - Google Patents

抗ｓ１００ａ４ヒト化抗体、使用及び方法

Info

Publication number
JP7824969B2
JP7824969B2 JP2023547272A JP2023547272A JP7824969B2 JP 7824969 B2 JP7824969 B2 JP 7824969B2 JP 2023547272 A JP2023547272 A JP 2023547272A JP 2023547272 A JP2023547272 A JP 2023547272A JP 7824969 B2 JP7824969 B2 JP 7824969B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
heavy chain
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509701A (ja
JPWO2022171656A5 (https=
JP2024509701A5 (https=
Inventor
ハレン，ジョナス
イクバル フセイン，リツワン
クリンゲルホファー，ジョーグ
バス，ティム
マッカン，ダラー
Original Assignee
アークス セラピューティクス エーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アークス セラピューティクス エーエス filed Critical アークス セラピューティクス エーエス
Publication of JP2024509701A publication Critical patent/JP2024509701A/ja
Publication of JPWO2022171656A5 publication Critical patent/JPWO2022171656A5/ja
Publication of JP2024509701A5 publication Critical patent/JP2024509701A5/ja
Application granted granted Critical
Publication of JP7824969B2 publication Critical patent/JP7824969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023547272A 2021-02-09 2022-02-09 抗ｓ１００ａ４ヒト化抗体、使用及び方法 Active JP7824969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147483P 2021-02-09 2021-02-09
US63/147,483 2021-02-09
PCT/EP2022/053095 WO2022171656A1 (en) 2021-02-09 2022-02-09 Anti-s100a4 humanized antibodies, uses and methods

Publications (4)

Publication Number Publication Date
JP2024509701A JP2024509701A (ja) 2024-03-05
JPWO2022171656A5 JPWO2022171656A5 (https=) 2025-08-20
JP2024509701A5 JP2024509701A5 (https=) 2025-08-20
JP7824969B2 true JP7824969B2 (ja) 2026-03-05

Family

ID=80446273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547272A Active JP7824969B2 (ja) 2021-02-09 2022-02-09 抗ｓ１００ａ４ヒト化抗体、使用及び方法

Country Status (8)

Country Link
US (2) US20240043521A1 (https=)
EP (1) EP4291579A1 (https=)
JP (1) JP7824969B2 (https=)
CN (1) CN117480182A (https=)
AU (1) AU2022219476A1 (https=)
CA (1) CA3207703A1 (https=)
IL (1) IL304971A (https=)
WO (1) WO2022171656A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531230A (ja) * 2020-06-30 2023-07-21 アークス セラピューティクス エーエス 全身性硬化症の治療のための抗ｓ１００ａ４抗体
EP4433084A1 (en) * 2021-11-19 2024-09-25 Lykera Biomed, S.A. Treatment and diagnosis of diseases associated to pathogenic fibrosis
CN115819577A (zh) * 2022-10-08 2023-03-21 河南赛诺特生物技术有限公司 一种抗s100a单克隆抗体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157724A1 (en) 2010-06-14 2011-12-22 Lykera Biomed Sa S100a4 antibodies and therapeutic uses thereof
WO2014068300A1 (en) 2012-10-30 2014-05-08 Cancer Research Technology Limited Anti-s100a4 antibody molecules and their uses
WO2019007075A1 (zh) 2017-07-06 2019-01-10 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL263272B2 (en) * 2016-06-14 2025-07-01 Merck Sharp & Dohme Antibodies to coagulation factor xi

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011157724A1 (en) 2010-06-14 2011-12-22 Lykera Biomed Sa S100a4 antibodies and therapeutic uses thereof
WO2014068300A1 (en) 2012-10-30 2014-05-08 Cancer Research Technology Limited Anti-s100a4 antibody molecules and their uses
WO2019007075A1 (zh) 2017-07-06 2019-01-10 北京多赢时代转化医学研究院 抗s100a4抗体在抗cd137抗体介导抗肿瘤免疫损伤中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Neoplasia，2012年，Vol.14，pp.1260-1268, Table W1
PLoS ONE，2013年，Vol.8, No.9, e72480，pp.1-17

Also Published As

Publication number Publication date
EP4291579A1 (en) 2023-12-20
IL304971A (en) 2023-10-01
US12304949B2 (en) 2025-05-20
JP2024509701A (ja) 2024-03-05
CA3207703A1 (en) 2022-08-18
AU2022219476A1 (en) 2023-09-21
WO2022171656A1 (en) 2022-08-18
US20250092125A1 (en) 2025-03-20
CN117480182A (zh) 2024-01-30
US20240043521A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
JP7730764B2 (ja) アンタゴニスト抗ｃｄ７抗体
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
JP2024059872A (ja) 新規抗ｃｃｒ８抗体
KR102663440B1 (ko) 인간화된 항-ccr7 리셉터 항체
CN112074536A (zh) 用于肿瘤特异性细胞清除的抗-cd25
US12304949B2 (en) Anti-S100A4 humanized antibodies, uses and methods
US20160194399A1 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
JP2020072715A (ja) 抗ｃｘｃｒ３抗体
US9505841B2 (en) Use of an anti-Ang2 antibody
JP2022514179A (ja) 新規アゴニスト抗ｔｎｆｒ２抗体分子
JP7843824B2 (ja) 抗体および使用方法
JP2022512905A (ja) 新規アンタゴニスト抗ｔｎｆｒ２抗体分子
US20230220058A1 (en) Anti-S100A4 antibodies for the treatment of systemic sclerosis
JP7430137B2 (ja) 抗体および使用方法
KR20240006519A (ko) 항-siglec 조성물 및 이의 용도
AU2022491825A1 (en) Humanized anti-human neurotensin receptor 1 antibodies and their uses
WO2022262749A1 (zh) 靶向pd1和/或ox40的特异性结合蛋白
CN114773485A (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260220

R150 Certificate of patent or registration of utility model

Ref document number: 7824969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150